DE602006011466D1 - Anti-ccr7-rezeptor-antikörper zur krebsbehandlung - Google Patents

Anti-ccr7-rezeptor-antikörper zur krebsbehandlung

Info

Publication number
DE602006011466D1
DE602006011466D1 DE602006011466T DE602006011466T DE602006011466D1 DE 602006011466 D1 DE602006011466 D1 DE 602006011466D1 DE 602006011466 T DE602006011466 T DE 602006011466T DE 602006011466 T DE602006011466 T DE 602006011466T DE 602006011466 D1 DE602006011466 D1 DE 602006011466D1
Authority
DE
Germany
Prior art keywords
ccr7 receptor
cancer treatment
receptor antibody
antibodies
ccr7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006011466T
Other languages
English (en)
Inventor
Calleja Cecilia Munoz
Perez Manuel Jesus Alfonso
Giral Sonia Lopez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Autonoma de Madrid
Original Assignee
Universidad Autonoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Autonoma de Madrid filed Critical Universidad Autonoma de Madrid
Publication of DE602006011466D1 publication Critical patent/DE602006011466D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602006011466T 2005-07-06 2006-07-05 Anti-ccr7-rezeptor-antikörper zur krebsbehandlung Active DE602006011466D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2005/007371 WO2007003216A1 (en) 2005-07-06 2005-07-06 Anti-ccr7 receptor antibodies for the treatment of cancer
PCT/EP2006/006556 WO2007003426A1 (en) 2005-07-06 2006-07-05 Anti-ccr7 receptor antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
DE602006011466D1 true DE602006011466D1 (de) 2010-02-11

Family

ID=36021798

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006011466T Active DE602006011466D1 (de) 2005-07-06 2006-07-05 Anti-ccr7-rezeptor-antikörper zur krebsbehandlung

Country Status (16)

Country Link
US (1) US8066996B2 (de)
EP (1) EP1904102B1 (de)
JP (1) JP5249025B2 (de)
KR (1) KR20080030655A (de)
CN (1) CN101257923A (de)
AT (1) ATE453407T1 (de)
AU (1) AU2006265281C1 (de)
BR (1) BRPI0612632A2 (de)
CA (1) CA2614080C (de)
DE (1) DE602006011466D1 (de)
DK (1) DK1904102T3 (de)
ES (1) ES2338919T3 (de)
IL (1) IL188594A (de)
PT (1) PT1904102E (de)
RU (1) RU2404808C2 (de)
WO (2) WO2007003216A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
WO2009139853A2 (en) * 2008-05-14 2009-11-19 Kim, Eldar Human monoclonal antibodies against human chemokine receptor ccr7
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
JP5801202B2 (ja) * 2009-09-29 2015-10-28 学校法人慶應義塾 抗腫瘍剤およびそのスクリーニング方法
NZ609154A (en) * 2010-09-28 2014-10-31 Sekisui Chemical Co Ltd Antihuman ccr7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
JP6469644B2 (ja) * 2013-03-15 2019-02-13 アムジエン・インコーポレーテツド 抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物
WO2015147335A1 (ja) * 2014-03-27 2015-10-01 国立大学法人大阪大学 脳マラリアの診断および治療
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
MX2018001596A (es) 2015-08-10 2018-05-02 Pepmab B V Anticuerpos anti-receptor ccr7 humanizados.
MA45819A (fr) 2015-10-09 2018-08-15 Sarepta Therapeutics Inc Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
FR2818747B1 (fr) * 2000-12-26 2003-05-16 Molecular Engines Laboratoires Procede de criblage base sur l'interaction siah-numb
US20020168358A1 (en) * 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
DE10248751A1 (de) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
WO2004104574A2 (en) * 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
US7807784B2 (en) * 2003-06-11 2010-10-05 The University Of Chicago Increased T-cell tumor infiltration by mutant LIGHT

Also Published As

Publication number Publication date
PT1904102E (pt) 2010-03-29
BRPI0612632A2 (pt) 2012-01-03
CN101257923A (zh) 2008-09-03
ES2338919T3 (es) 2010-05-13
CA2614080A1 (en) 2007-01-11
EP1904102A1 (de) 2008-04-02
DK1904102T3 (da) 2010-04-19
EP1904102B1 (de) 2009-12-30
ATE453407T1 (de) 2010-01-15
RU2008104420A (ru) 2009-08-20
AU2006265281C1 (en) 2012-11-15
RU2404808C2 (ru) 2010-11-27
CA2614080C (en) 2014-08-26
AU2006265281A1 (en) 2007-01-11
JP2008545000A (ja) 2008-12-11
IL188594A (en) 2012-02-29
JP5249025B2 (ja) 2013-07-31
KR20080030655A (ko) 2008-04-04
US8066996B2 (en) 2011-11-29
WO2007003426A1 (en) 2007-01-11
US20090123483A1 (en) 2009-05-14
WO2007003216A1 (en) 2007-01-11
IL188594A0 (en) 2008-04-13
AU2006265281B2 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
DE602006011466D1 (de) Anti-ccr7-rezeptor-antikörper zur krebsbehandlung
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
MD3328888T2 (ro) Anticorpi anti-PSMA, molecule de legare a antigenelor bispecifice care leagă PSMA și CD3 și utilizările acestora
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
PH12016501384A1 (en) Human antibodies to pd-l1
DOP2012000052A (es) Proteínas terapéuticas de unión a dll4
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
MX2021009852A (es) Anticuerpos humanos para pd-1.
EA201170716A1 (ru) Антитела к с-мет
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
EA201590144A1 (ru) Rspo3-связывающие агенты и их применение
GT200900002A (es) Anticuerpo antagonista para el tratamiento del cancer
MX349198B (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
UY31466A1 (es) Anticuerpos monoclonales que se unen al hgm-csf y las composiciones médicas que los comprenden
EA201100923A1 (ru) Антитела человека против тканевого фактора
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
EA201171237A1 (ru) Антитела к dkk-1
ATE528319T1 (de) Krebsbehandlung mit anti-il-1-antikörpern
NZ601943A (en) Antibodies against cxcr4
EA201892094A1 (ru) АНТИТЕЛА К ФНО-α И ИХ ФУНКЦИОНАЛЬНЫЕ ФРАГМЕНТЫ
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
EA202091974A1 (ru) Связывающие bcma антитела и их применение

Legal Events

Date Code Title Description
8364 No opposition during term of opposition